Printer Friendly

GENEREX PRESENTS POTENTIAL USES OF RAPIDMIST.

Generex Biotechnology Corporation (NASDAQ:GNBT), Toronto, has presented a research abstract by Robert Humphreys, the chief scientific officer of its Antigen Express immunomedicines subsidiary, at the Foundation Merieux Conference, "Innate and Adaptive Immunity after Transcutaneous or Mucosal Vaccination." The conference was held in Annecy, France. Dr. Humphreys presented: "Transmucosal Delivery of Therapeutics by RapidMist(R) Technology and TH-1 T-helper cell Ii-Key/MHC Class II Peptide Vaccines against Cancer and HIV."

Dr. Pankaj Modi, the inventor of the technology at Generex, developed a novel method for aerosolized delivery of proteins and peptides through the buccal mucosa by a RapidMist(R) device using a pressurized fluorocarbon. The administering device, formulations and methods have been validated with insulin, for treatment of diabetes. The administered insulin is absorbed rapidly and provides a therapeutic plasma level within 20 minutes of application.

This device also enables needle-less, pain-free, repeated, low-dose administration of immunomodulatory peptides for the treatment of asthma and some autoimmune diseases. Control of such diseases might require frequent, low-dose administration of immunomodulatory peptides, which shut off pathological immune responses of the disease.

The potency of antigenic epitope-containing immunomodulatory peptides is further enhanced by a second Antigen Express, Inc. technology, based on the Ii-Key peptide. The Ii-Key motif from the Ii protein acts at an allosteric site adjacent to the MHC class II antigenic peptide-binding trough to enhance presentation of covalently linked epitopes 200-500 times in vitro.

Such hybrid peptides can also be used as vaccine peptides for the therapy of cancer and infectious diseases. In vivo vaccination of mice with such Ii-Key/MHC class II epitope hybrids enhances immune responses to antigenic epitopes from cancer-related antigens for breast, colon, and ovarian carcinomas, melanoma and HIV.

The potency of other vaccine peptides is also greatly increased when linked to the Ii-Key active molecule. Antigen is pursuing programs for the use of such vaccines for HIV, SARS, and smallpox. Hybrids of the Ii-Key linked chemically to an antigenic epitope are potent vaccines in mouse models of human diseases.

Antigen Express has received 9 grants from the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, and the Department of Defense for the development of these compounds for many vaccine and treatment purposes.

"We are very pleased to project the use of our RapidMist(R) technology in the vaccine applications of Antigen Express," Anna Gluskin, CEO of Generex said. "In cases where antigenic immunoregulatory peptides developed by Antigen Express must be administered twice a day, to control a disease process such as an acute flare in multiple sclerosis, only the needless RapidMist(R) method of administration will be accepted by patients and physicians."

About Generex

Generex is engaged in the research and development of drug delivery systems and technology. To date, it has focused on developing a platform technology for the buccal delivery -- delivery to the oral cavity for absorption through the inner mouth mucosa -- of drugs that historically have been administered only by injection. Generex's buccal delivery technology has application to a large number of drugs. Generex acquired Antigen Express in August. 2003. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.

For more information, call 800/391-6755 or 416/364-2551 or visit http://www.generex.com.
COPYRIGHT 2004 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Biotech Equipment Update
Geographic Code:1USA
Date:Aug 1, 2004
Words:543
Previous Article:SIEMENS DEBUTS 64-SLICE COMPUTED TOMOGRAPHY SCANNER.
Next Article:EV3/INVTEC FORM DISTRIBUTION ALLIANCE.
Topics:


Related Articles
GENEREX REPORTS A NET LOSS OF $2.6 MILLION FOR THIRD QTR.
Generex Biotechnology announces grant of European patent for aerosol delivery.
Generex Biotechnology receives Japanese patent for technology to enhance T helper cell recognition of cancer and bioterrorism antigens.
Generex Biotechnology receives Japanese patent for technology to enhance T helper cell recognition of cancer and bioterrorism antigens.
Generex receives Australian patent for vaccine technology.
Generex files application for oral/buccal metformin patent.
Business briefs.
GENEREX GETS APPROVAL FOR ORAL-LYN PHASE III TRIAL.
GENEREX AWARDED PATENTS IN NORTH AND SOUTH AMERICA.
BRIEFS.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |